Edited with the trial version of
Foxit Advanced PDF Editor
To remove this notice, visit:
www.foxitsoftware.com/shopping

Thu5c &2
4
&#
#
&(8
/
:
"


"0
$" 

!! $$

%#$"$
&'#
"  )
($
$ 
>
4
<
 


6


58g.
4w8
4q.(
)v0
2"
$?$
)/2-/.&
#\.
$)]4
0&04*%
#"/
(p-
insulin
(,5$"(/.

6>
3/-"4/34"4*.
"
)/2-/.&
42A.
,^.
,Ov4
KOv$
4*g4
2"
4z
4g
#>/
Q
P
R
$x"

4*i5
K\/
".(&2)".3
)|.(
)/2-/.
.>8
$E
6"*
42D
15".
42m.(
42/.(
K*h5

)D"
$?$
15?
42B.)
$)58i.
)E"
Kd$
#*k4
,>
(*|
$)/
KOt.(
)58g4
q.
Kl.)
}

4)*g5
)w4
*.35,*.
4ON.(
Ko*
)/d$
458k4
Ko*
42/.(
K?*
4)?/
KOt.(
,>
$E
4)i

%`.
4s*
4B.)
42[.(
4I.(
KOt.(
)58g4
.()*A-
42m.(
h
,@5
%>*
#k.)
.)@.

+)F.(
KOv$
K*h5
42l
4o4
$?$
#*g.
$)y.(
42A.
6G.(
-[$
4)^.
+*.)
4)a.
6>

4*-
-[$)
3f
75]4
)*k.
J*h5
42l
#c.(
$?$
$)g
0)_-
*.35,*.
)/d$
$?$
4)5o$

K*h5
42l
K?*
4)?/
KOt.(
+)?$
\.(

3f
,>-
(*\-
4
,k
#*g.
$)y.(
6>
4{

6/.(
,*A.
15".
Kg.
K?*
4)?/
KOt.(


II. B3NH %!

!
%'7


INSULIN

Insulin aspart NOVOLOG

Insulin detemir LEVEMIR
Insulin glargine LANTUS
Insulin glulisine APIDRA
Insulin lispro HUMALOG
NPH insulin suspension HUMULIN N,
NOVOLIN N

Regular insulin HUMULIN R, NOVOLIN R
AMYLIN ANALOG

Pramlintide SYMLIN
ORAL AGENTS

Acarbose PRECOSE
Alogliptin NESINA
Bromocriptine CYCLOSET
Canagliflozin INVOKANA
Colesevelam WELCHOL
Dapagliflozin FARXIGA
Glimepiride AMARYL
Glipizide GLUCOTROL
Glyburide DIAΒETA, GLYNASE PRESTAB
Linagliptin TRADJENTA
Metformin FORTAMET, GLUCOPHAGE
Miglitol GLYSET
Nateglinide STARLIX
Pioglitazone ACTOS
Repaglinide PRANDIN
Rosiglitazone AVANDIA
Saxagliptin ONGLYZA

Sitagliptin JANUVIA
Tolbutamide TOLBUTAMIDE


,k
-b$
K?*
4)?/
KOt.(
K".(
(*"
4I.(
$)E.(
-d4
4[*
€
$M.(
.)O

42A.
4/>.
4)g
(*s*
.(Ot*
4"
Os$
4C.)
$E


42*k5
.(Ot*
€
6>




42*k5
.(Ot*
42A.
4/>.
4)g
(*s*
K".(
0)\*
,>-
#[.
6s*
$I.
#k.)
.>8

J?*
4)?/
KOt.(
+)F.(
0)\*
,>
-r4
#k.)
KN.
4)5^.
->
,>
-r4
.)E-

$?$
)r*
$)y.(
KOv$
Kd$
42O.(
$)5.(
#u*
4B.)
42[.(
4I.(
KOt.(
)58g4

%/
4)*g5
)w4
4ON.(
Ko*
)/d$
458k4
Ko*
*.35,*.
*k0
)r*
K?*
4)?/
KOt.(

€

0)@.
K?*
4)?/
KOt.(
JJ
4)>.)


.)E-
JJ
480&


JJ
480&

JJ
4)"*
+~
6>
$?$
4)i
Kd$
#*k4
(@8
2"
#u*
.(58A.
.)@.

+)?$
.)O
%*
4258h.
4)5o$
\.(

4E-
4b4
.)|.(
K*i-
Kd$
42O.(
$x"

K?*
4)?/
KOt.(
480&

6>
480&

J?*
4)?/
KOt.(
4)"*
+~
KOv$
Kl.)

.()L"
,>
3}
2p*
,/[.
%5.(
.[0
(,5$/3&
+)u*
0)?4
)/d$
KOv$
$)_.
K/?.

,^.
K^5
42/.(
,H$
-".(
4)"*
J?*
4)?/
KOt.(
4)"*
+~
+)F.(
KOv$
+*i-

3/?4
4o4
$E
4)i
%`.
4s*
3*.)
$/.
4/
+)E
3*.)
$M.(
.)O
)[
KOt.(
)58g4

u
42e
KOv$
3*.)
2"
#u*
4)"*
0)w
-b$
#k.)
)g
Kr
I.
,>.)
-[.)
4a0

4)i
%w$
6>)/d$
3{
%w.(
*.35,*.
$E
)*k5
15\
4o4
$)/
.)|.(
#k.)
.)@.
INCRETIN MIMETIC
K?*
4)?/
KOt.(
4)"*
+~
&4'/2-*.
6>
,8#52*%&
$E
4)i
3{
%w.(
4)"8
Exenatide BYETTA, BYDUREON
Liraglutide VICTOZA
4)g
*.35,*.
42/.(
K*h5
42l
K?*
4)?/
KOt.(
4)"*
+~
A. %#
#
&(8



JJ
480&

4)Ot.(
(d0
u
42e
.)n
4)".)
4)*g5
.*A.
)/d$
.(Ot*

42e
45q*
u
-r4
3o
4)i
%*j.
4*g.
$)a-
#k.)
$E
4)i
75]4
)*k.
u

,y"
45q*
-5r.
)N.
JJ
480&

KOv$
Kd$
42O.(
#u*
3}
4)*g5
)w4


458k4
Ko*
*.35,*.
%/
4g
#>/
Q
#l
0)?
)x8
g
#>/
Q
#l
0)?
)x8

$E
4)i
,>
+g4
15\
$x"
15?
42B.)
4}
-*j.
KOv$
+)N*
->/
#u*
4?$

.)@.
*253
)/d$
$?$
$)]4
Kr$
4z
-F*
42Ot.(

0002116803.INDD 335

B1ng 1
1 $;$
/
$%?
#A
@

$" 
3=%
$">
22

6/23/2014 8:28:59 AM


Edited with the trial version of
Foxit Advanced PDF Editor
To remove this notice, visit:

www.foxitsoftware.com/shopping

 
 


Type 1

Type 2

Tuổi khởi phát 5J
B!


5J
#%



$%I

Thể trạng


'
B!
0

!1

K
$"C


5J
$"C
$%I
A'

Tỷ suất mắc

5% - 10%

90% - 95%

Liên quan di
truyền

M
!?

@$
>

Thiếu hụt,
khiếm
khuyết insulin

D
-
6 G


!.
L'
@$

?
2
$D$

#%

H
 >
$D$

#%
.

#%
.
"H

 >
.

g
%?0
T
.`5
,*_
/N/)
*0^5
Pr/)
569g/
5x9
,*I/)
P+h6
*G$
PSw&
PSt/)

*69g5
7?
%k/*
/*A/
O O
591(


&H
/*|/)
53+k6
&*z/)
P+i/
*E/*
&y$

5*+g6
*x5
+/46-+/
M/
/*+h6
6o/)
/*+h6
5+i6
/*+h6
)a9
/*+h6
k/*

/*A/
O O
591(


%d5
%6r&
1*_+
4{
'x/)
+/46-+/
Pi
53@/*
/*|/)
&R/

5N/)
PSt/)
*69g5
/)*+D.
53n/)
7?
/)69
*+i.
5F/*
.^/)
'0
/*+j.

50$/
&(50/(

"
!
u
/)St+
%E/*
5*St/)
4$6
,*+
N/
1045$%40315+7(
5g

%?0
T
-6I/
5+g5
3$
.r5
-Sw/)
+/46-+/
*e/)
Pm/*
Pi
'69
53E
.z&
+/46-+/

/h/
O+h6
/?9
P_.
%_0
26@
53E/*
'm
*H$
-+1+'
1305+'
7?
)-9&0)(/

,*I/)
8_9
3$
$6
,*+
N/
,*0_/)

1*K5
5g
%?0
T
5+g5
3$
.r5
-Sw/)

+/46-+/
Pi
P@1
z/)
7s+
4}
5N/)
)-6&04(
7?
$&+'
$.+/
530/)
.@6
6@

53E/*
/?9
,C0
'?+
,*0_/)


1*K5
5+g1
4$6
PH
-?
26@
53E/*
5+g5
+/46-+/

4$6
N/
69
/*+D/
v
%k/*
/*A/
O O
591(


5g
%?0
T
%m
1*@
*y9
7?

,*I/)
5*i
P_.
%_0
Py
+/46-+/
/h/
&Q/)
/*S
-Sw/)
+/46-+/
&a/
Pi

P@1
z/)
7s+
5*$9
Pq+
/p/)
Pr
)-6&04(
530/)
.@6
_/)



#&
' Bk/*
/*A/
O O
591(



%6r&
1*_+
'J/)
+/46-+/
Pi
53@/*

5N/)
PSt/)
*69g5
/*+j.
50$/
&(50/(
7?
'69
53E
%

v
.z&
&*`1

/*c/
PSw&
x&
5+D6
P+h6
53m
7s+
+/46-+/
-?
'69
53E
PSt/)
*69g5
)a/

.z&

4+/*
-L
/*`5
&H
5*i
7?
53@/*
/*|/)
5*$9
Pq+
-s/
&y$
PSt/)
*69g5

*+
P+h6
53m
7s+
+/46-+/
5}
,+i.
53$
PSt/)
*69g5
5*St/)
869D/
%e/)

.@9
P0
PSt/)
5^+
/*?

Bng 2

#.
33
$'!

&-
$'!



##


O O
591(

&*+g.
Pg/
*R/

&@&
53St/)
*w1
O O
k/*
%m
_/*

*Sv/)
%v+
&@&
9g6
5o
/*S
'+
5369h/
56q+
%C0
1*E
,*@/)
+/46-+/
v
/)0^+

%+D/
*R/
-?
26@
53E/*
5}
.+j/
/*S
530/)
O O
591(


@&
3o+
-0^/
&*69i/

*H$
530/)
O O
591(

,*I/)
3a.
3r
/*S
530/)
O O
591(


!
%k/*

/*A/
O O
591(

5*St/)
,*I/)
%m
/*+j.
50$/
&(50/(
/*S/)
&@&
%+g/

&*z/)
.^/
5F/*
v

5*i
-?
5SR/)
5}
/*$6




 

µ
µ
Người khỏe mạnh
80

ĐTĐ type 2
40


ĐTĐ type 1
0

0

5
Phút

10

Truyền glucose TM




D$ #% K
5J
1
$5J
&-
F

/
33

$"%'E
% #
$4
>

0002116803.INDD 336

 "
! O O
591(

Pf&
53S/)
%v+
5E/*
53^/)
,*@/)
+/46-+/


&R
26$/
PF&*
5*+g6
/*^9
&_.
7s+
+/46-+/
_/)


30/)
O O
591(


.f&
'J
5g
%?0
T
7b/
&G/
,*_
/N/)
*0^5
Pr/)
/*S/)
-Sw/)
+/46-+/

5+g5
3$
,*I/)
Py
Pi
P+h6
*G$
PSt/)
*69g5
_/)


,*+
)f1
1*_+
5E/*

53$/)
,*@/)
+/46-+/
/)?9
&?/)
5N/)
v
/)0^+
%+D/
*o+
-Sw/)
5g
%?0

T
)+_.
'a/
5*(0
5*t+
)+$/
.d&
%k/*
3@+
7s+
O O
591(


%k/*

/*A/
O O
591(

5*St/)
%C0
1*E
C0
1*E
-?
.r5
530/)
/*|/)
9g6
5o


)H1
1*a/
5^0
3$
5E/*
53^/)
,*@/)
+/46-+/

9g6
5o
PSw&
&0+
-?
/)69D/

/*A/
&*F/*
)A9
O O
591(

 #&
'
x&
5+D6
P+h6
53m
O O
591(

-?
'69
53E
PSt/)
*69g5
530/)

)+s+
*^/
%E/*
5*St/)
7?
/)N/
&*f/
53E
*0B/
5+g/
53+i/
&y$
&@&
%+g/

&*z/)
.^/
5F/*
+_.
&A/
5c1
5*i
'x&
P+h6
&*l/*
&*g
Pr
N/
-?.

)+_.
,*@/)
+/46-+/
7?
)+K1
.r5
4o
%k/*
/*A/
P^5
.z&
PSt/)
*69g5

.x&
5+D6
569
/*+D/
*a6
*g5
&@&
%k/*
/*A/
Ph6
1*_+
4{
&@&
5*6o&
6o/)

P+h6
53m
O O
*(0
'+j/
5+g/
%k/*
5g
%?0
'a/
T
469
,+k5
,*+
PH
+/46-+/

5*St/)
PSw&
4{
'x/)
Pi
PS$
PSt/)
*69g5
7h
.z&
.x&
5+D6
_/)


6/23/2014 8:29:00 AM


Edited with the trial version of
Foxit Advanced PDF Editor
To remove this notice, visit:






www.foxitsoftware.com/shopping

III. INSULIN VÀ INSULIN ANALOG
+02)'+
);
&,/*,+#
!B
U+
!&V1
-#-1'"
!V2
1T,
1q
&'
!&2g'
-#-1'"
GKm!
+d'

3i'
+&2
[+%
*h1
!W2
+d'
"'02)$'"#
q
1'_+
!&V1
-/,'+02)'+
(&'
b
1&o5
-&=+
1T,

1&;+&
'+02)'+
3;

-#-1'"#
!U
&'
G_2
GKm!
1'^1
/
1q
125^+
1n5
K2
D

+02)'+

b
1&U'
1/q
.2
%+
3;
1&Y+
",
GB
+e+%
Gh
'+02)'+
1/,+%
*<2
(&C+%
-&U+
<+&

!&@+&
4 -#-1'"#


0]
!&,
+&s+%
!,+
0d
!&@+&
4#U
'(Q
)1"
!O!
9Q
("&
Q'
&N

 !
2
"% "!
2
)1
2

'(N
9!
&V
U!

!O!
9Q
("&
2(
"
&J
1
'8!
:T!
("&

)1"
'K
1"
C
'(*K!
'U*
$(
2
3!
)H!
(*L!
D
'(*K!
'U*
("&
9:T

#"&#"%*
6
R
!+* 
("&!&

!+* 
"D'
9Q!
!:
Q'
Q
#H!

!H!
E
!&(!

("&
&(

9:T
#"&#"%*
6
&J
9
)1"
(P
7
F#

'K
1"
)1
'D"
%

O!
9Q

'8!
"
&J
"
3!

1
V
W

1!
'K
1"
1
 '%1!
)1"
!Q
1"
O!
9Q

!Q
1"
'8!
kích
thích
'U*
#6!
'5
!&(!
'"
!M#
A. C

#


'


15-#

&,\!
f
02+%
)Km+%
'+02)'+
1&'^2
&n1
1/,+%
FF
15-#

"n+%
'+02)'+
+%,T'
0'+&
1KJ+%
1t
+&K
+h'
0'+&
B. D&

%


$


+02)'+
+%Kj'
GKm!
1f+%
&m-
+&j
!C+%
+%&a
1<'
1f
&m-
0r
"n+%

!!&o+%


,)'
&,\!
+V*
*#+
'^+
Gf'
%#+#
&'
1&5
Gf'
*h1
0d
!'"

*'+
1/,+%
'+02)'+
+%Kj'
0]
1T,
/
!+),%
!B
G\!
1@+&
"Km!
Gh+%
&c!
(&F'`*
(&
6
'2
U!
3;
'S
!
(*
'%4
'2
U!
@
"n
!&(!
&#%'

!&(!
&#%"
!&(!
(&!
!B
1&j'
%'+
(&k'
-&<1
3;
"25
1/?
1"n+%
+%Z+
&J+
0,
3i'
!&(!
':S!
'_2
0r
"n+%
3b
1/@
1'>*
*p!

Gh
1Ki'
*<2
+&'a1
Gh
3;
!&Kk+%
G^+
1&j'
%'+
(&k'
-&<1
3;
"25
1/?
1'+02)'+
,
!B
U+
!&V1
-,)5-#-1'"
+>+
!GKj+%
1'>2
&B
(&'
2d+%
?
3Y5
'+02)'+
1&Kj+%
GKm!
1'>*
"Ki'
"

1/,+%
1/Kj+%
&m-
!V-
!p2
",
1E+%
GKj+%
&25^1
+\+%
!B
1&`
1'>*
1H+&

*T!&
'+02)'+
1&Kj+%
%,;'
/
+%Kj'
1
!A+
0r
"n+%
-&KJ+%
-&<-

1/25_+
)'>+
1n!
'+02)'+
"Ki'
"
!A+
%c'
);
J*
'+02)'+
&KJ+%
-&<-

+;5
(&<
1'a+
)m'
+B
1/<+&
-&U'
1'>*
+&'_2
*I'
'+02)'+
1/,+%
+%;5

),T'
J*
'+02)'+
GKm!
)Y-
1/?+&
G`
"25
1/?
*p!
'+02)'+
+_+
%,;'
/

+B
!I+%
!2+%
!V-
1&>*
!&,
a+&
+&=+
1&>*
*h1
)Km+%
!&(!
!!
G`
4r
)D
)Km+%
!/ ,+&5"/1#
GK
3;,
(&'
E+
E+
&,\!
G<-
p+%
(&'

%)2!,0#
*<2
1E+%
!,

1

Kháng insulin ở
ngoại biên
Gan
Tăng tổng
hợp glucose

Glucose

Giảm thu nhận
glucose


Cơ

MÔ MỠ

Tế bào β tiết insulin
không đầy đủ

2

Insulin
Tuyến tụy
B"ng 4
!
1 4

$
"
%
'(7

1

&
&




Rối loạn
dung nạp
Bình
thường Glucose

Re
lat
ive

ab
ility

to

Không
điều trị

0–5
năm

ĐTĐ type2
5–15
Trên
năm
15
năm

sec
rete
insu
lin

Ăn
kiêng

Ăn kiêng Phối
+
hợp
metformin thuốc

Insulin
nhiều

mũi

Diễn tiến bệnh nặng dần

C. Tác d'ng ngo!i ý c(a insulin

T
GKj+%
&25^1
);
1<!
"n+%
-&n
+%&'>*
1/c+%
3;
1&Kj+%
%\-
+&V1

!o
'+02)'+
 U+%


p+%
3;
),T+
"Kl+%
*l
!&g
1'>*
,T+
"Kl+%
*l
!B
1&`
GKm!
&T+
!&^

[+%
!<!&
1&5
Gf'
3b
1/@
1'>*

a+&
+&=+
025
1&Y+
!B
1&`
!W+
%'U*

)'_2

0002116803.INDD 337

B"ng 5
(8

6



7


0

&
&



 # 9
'2
3



5

'/

6/23/2014 8:29:02 AM


Edited with the trial version of

Foxit Advanced PDF Editor
To remove this notice, visit:
www.foxitsoftware.com/shopping

namud.vn - Cng 








Triệu chứng hạ
đường huyết

Đau đầu

Hồi hộp

IV. CÁC CH



INSULIN TRONG 


!
168/-1
QUy(
(,-&
7,A1,
168/-1
1,&1,

&3-)
&(7-1+
168/-1
7,w-
+-&1

)8;
75G
7B(
)z1+
1+d1
 ,257
&(7-1+
7581+
'G1,
17*50*)-&7*
&(7-1+
9A

)A-
21+
&(7-1+
_1+


7J0
7d7
7,w-
+-&1
.,x-
3,B7
7B(
)z1+
Q^7
Qn1,

7521+
0B8
9A
)8;
75G
7B(
)z1+
({&
(B(
/2^-
-168/-1
Pr-
9v-
(B(
'B(
6R

.,-
6~
)z1+
-168/-1
(a1
7,c1
75p1+
Qg(
'-m7
(,M
N
Qi1
/-j1
)L1+
9A
/2^-

-168/-1
QC;
/A
Q-j8
5`7
48&1
75p1+
A. Insulin nhanh và insulin th"

Đánh trống ngực


Lú lẫn

Chóng mặt

Toát mồ hôi

Run

Đói cồn
cào

Nhìn mờ

A

A

A

Mệt mỏi rã
rời

Loạn dưỡng mỡ

Quá mẫn



!


. .

/

+
'-
-

#
+


,

#
%+
$
-
&
"


0002116803.INDD 338

J

(,i
3,b0
-168/-1
7,8u(
1,J0
1A;
 
'5